NR4A1 and breast carcinoma: In a phase 3, randomized, placebo-controlled trial (BELLE-2), the addition of buparlisib to fulvestrant significantly prolonged PFS (6.9 vs.5.0 months, HR0.78, one-sided p = 0·00021) compared with the placebo plus fulvestrant group in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer [123].